Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Summit Therapeu ADR
(NQ:
SMMT
)
20.10
-1.80 (-8.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Summit Therapeu ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Is Summit Therapeutics Stock a Buy?
September 30, 2024
Its alliance with a successful foreign biotech could be decisive for the stock.
Via
The Motley Fool
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
September 29, 2024
10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio?
Via
Benzinga
2 High-Potential Growth Stocks You Shouldn't Overlook
September 29, 2024
These two growth stocks have plenty of room to run.
Via
The Motley Fool
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
September 28, 2024
One of them is performing much better than the other this year.
Via
The Motley Fool
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
September 25, 2024
These relatively small companies are developing new cancer therapies that could generate billions in annual sales.
Via
The Motley Fool
Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today
September 13, 2024
Via
Benzinga
Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
September 11, 2024
Via
Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
September 22, 2024
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%
Via
Benzinga
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
September 22, 2024
How long will the momentum last?
Via
The Motley Fool
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Via
AB Newswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge.
Via
News Direct
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
September 19, 2024
The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study.
Via
The Motley Fool
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
September 18, 2024
There's a lot of hope for ivonescimab, but are investors being a bit too bullish?
Via
The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
September 17, 2024
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.
Via
Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival...
Via
Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
September 17, 2024
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Via
The Motley Fool
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
September 16, 2024
Via
Benzinga
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
September 16, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
September 15, 2024
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.
Via
Benzinga
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
September 14, 2024
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.
Via
The Motley Fool
Why Summit Therapeutics Skyrocketed 123% This Week
September 13, 2024
Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers.
Via
The Motley Fool
Why Summit Therapeutics Stock Is Soaring Again Today
September 12, 2024
This high-flying biotech stock is moving even higher -- and for good reason.
Via
The Motley Fool
Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
September 12, 2024
Via
Benzinga
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
September 12, 2024
The company is adding onto its success outperforming Merck's top drug in lung cancer patients.
Via
Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
September 12, 2024
Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab.
Via
MarketBeat
Why Summit Therapeutics (SMMT) Stock Is Rising Today
September 12, 2024
Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net proceeds.
Via
Benzinga
Summit Therapeutics Raises $235 Million
September 12, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Is Summit Therapeutics a Buy Now?
September 10, 2024
The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.
Via
The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
September 09, 2024
The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.
Via
The Motley Fool
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
September 09, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.